JNK Protein Triggers Nerve Cells to Withdraw Their Synapses when Stressed
Blocking activation of the JNK protein in synapses stops synapses from retracting. Temporal colour coding shows that when the JNK protein is inhibited in synapses using a light beam, a structural protein called “actin” freezes in time. Changing the cells cytoskeleton is part of an array of molecular events that JNK triggers to destabilize synapses.
Synapses are tiny cell protrusions where electrochemical impulses pass between nerves. Prolonged stress in the brain causes synapse withdrawal and maladaptive changes to circuits that are linked to the development of major depressive disorder.
Postdoctoral Researcher Patrik Hollós and colleagues used a light-activated optogenetic tool to switch off the activity of a protein called JNK specifically in synapses.
– Using a light beam to inhibit the JNK protein prevented synapses from shrinking in response to stress. Specifically the internalisation of a receptor called “AMPAR”, an early event in synapse disassembly, was blocked, explains Hollós.
JNK Is a Stress Sensor in Synapses and May Elicit the Effects of Ketamine
Researchers also found that the novel, fast-acting anti-depressant ketamine inhibited the JNK protein while preventing synapse retraction.
– These results show that the JNK protein is a stress sensor in synapses. When activated, it triggers the disassembly of synapse machinery followed by rapid synapse regression. Conversely, inhibiting the JNK protein makes synapses able to withstand chronic endocrine stress. This may be relevant for conditions where hormonal stress leads to synapse elimination but also to control synapse number under normal homeostatic conditions, says team leader Eleanor Coffey.
These findings help us to understand how stress dismantles synapses, and provides clues for novel targeted therapies.
The study was published as a research highlight in the open access journal of the Society for Neuroscience, eNeuro.
Research was conducted at Turku Bioscience Centre a joint research facility of the University of Turku and Åbo Akademi University.
For more information contact Research Director Eleanor Coffey, Turku Bioscience, eleanor.coffey@bioscience.fi
Recent Posts
- Dissertation Defence: Eleftheria MaranouMSc Eleftheria Maranou, from affiliated MIORG group, succesfully defended the dissertation in Immunology titled “The Achilles’ heel of Read moreSeptember 1, 2026
- Researchers discover molecular mechanism that helps aggressive colorectal cancer to spreadResearchers from the University of Turku in Finland, Turku Bioscience Centre and Gustave Roussy Institute Read moreAugust 25, 2026
- The Novo Nordisk Foundation has awarded funding of approximately one million euros to a research project led by Professor Jukka WestermarckThe Novo Nordisk Foundation has awarded funding of approximately one million euros to a research Read moreAugust 21, 2026
- The Jane and Aatos Erkko Foundation has granted nearly €1 million to support research led by Professor Jukka Westermarck993 000 € was granted to a research project led by our Group Leader Professor Jukka Read moreApril 2, 2026
- Cecilia Sahlgren’s group discovers a new mechanism driving breast cancer progressionOur affiliated research group led by Professor Cecilia Sahlgren at Åbo Akademi University and the InFLAMES Research Read moreMarch 25, 2026
- BioCity Turku asks for proposals for Elias Tillandz publication prize winner during March 2026In the context of the 35th BioCity Symposium “Vision, Expanded” (27-28 August 2026) the twenty-second Read moreMarch 3, 2026